Drugs / StroMed
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02844751 | Jul 2015 → Aug 2026 overdue | osteoarthritis, knee | VivaTech International, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT02844738 | Jul 2015 → Aug 2026 overdue | osteoarthritis | VivaTech International, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT02844764 | Jul 2015 → Aug 2026 overdue | osteoarthritis | VivaTech International, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Stromed | “Patients will be treated with autologous Stromed obtained by the Adipose Ultrasonic Cell Recovery Unit” NCT02844738 ↗4“autologous Stromed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU)” NCT02844751 ↗ |
| Modality | Cell therapy | “autologous cell therapy” NCT02844738 ↗ |
| Route | Other | “each as direct injections to the affected joints” NCT02844738 ↗ |